Report from the EPAA workshop: In vitro ADME in safety testing used by EPAA industry sectors

Toxicology in Vitro

Volumn 25, Issue 3, 2011, Pages 589-604

  Schroeder, K ^a,s   Bremm, K D ^b   Alepee N ^c   Bessems, J G M ^d   Blaauboer, B ^e   Boehn, S N ^f   Burek, C ^g   Coecke, S ^h   Gombau, L ⁱ   Hewitt, N J ^c   Heylings, J ^j   Huwyler, J ^k   Jaeger, M ^l   Jagelavicius, M ^m   Jarrett, N ⁿ   Ketelslegers, H ^o   Kocina, I ^p   Koester, J ^q   Kreysa, J ^h   Note, R ^c   Poth, A ^l   Radtke, M ^b   Rogiers, V ^r   Scheel, J ^s   Schulz, T ^t   Steinkellner, H ^u   Toeroek, M ^v   Whelan, M ^h   Winkler, P ^w   Diembeck, W ^x   more..

^a Zet Life Science Laboratorium   (Austria)

^b BAYER PHARMA AG   (Germany)

^c L'Oréal Life Sciences ^*  (Germany)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f BASF SE   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h JOINT RESEARCH CENTRE   (Italy)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j KEELE UNIVERSITY   (United Kingdom)

^k UNIVERSITY OF APPLIED SCIENCES AND ARTS NORTHWESTERN SWITZERLAND   (Switzerland)

^l Harlan   (Switzerland)

^m State Plant Protection Service   (Lithuania)

ⁿ EUROPEAN MEDICINES AGENCY   (United Kingdom)

^o EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

^p Food and Veterinary Service of the Republic of Latvia   (Latvia)

^q BAYER CROPSCIENCE AG   (Germany)

^r FREE UNIVERSITY OF BRUSSELS   (Belgium)

^s HENKEL KGAA   (Germany)

^t FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^u EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

^v ACTELION PHARMACEUTICALS LTD   (Switzerland)

^w JOHNSON AND JOHNSON   (United States)

^x BEIERSDORF AG   (Germany)

more..

Author keywords

ADME; EPAA workshop; In vitro; Safety testing

Indexed keywords

COSMETIC; PESTICIDE;

ANIMAL TESTING ALTERNATIVE; ANIMAL TESTING REDUCTION; BIOSORPTION; CHEMICAL INDUSTRY; COMPUTER MODEL; DRUG INDUSTRY; DRUG SAFETY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFORMATION DISSEMINATION; LIVER CLEARANCE; MICRODOSIMETRY; NONHUMAN; PARTICIPATORY MANAGEMENT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE; STANDARDIZATION; TOXICITY TESTING; WORKSHOP;

ANIMAL TESTING ALTERNATIVES; ANIMALS; CELLS, CULTURED; COMPUTER SIMULATION; CONGRESSES AS TOPIC; EUROPE; INDUSTRY; INTERNATIONAL COOPERATION; MODELS, CHEMICAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; XENOBIOTICS;

ANIMALIA;

EID: 79952037725     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.12.005     Document Type: Review

References (117)

1. Avdeef A., Artursson P., Neuhoff S., Lazorova L., Grasjo J., Tavelin S. Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA pK(a)(flux) method. European Journal of Pharmaceutical Sciences 2005, 24:333-349.
2. Archer G.E.B., Liebisch M. The ECVAM international validation study in vitro for skin corrosivity. Toxicology In Vitro 1998, 12:483-524.
3. Bal-Price A., Brown G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. Journal of Neurosciences 2001, 21:6480-6491.
4. Barton H., Pastoor T.P., Baetcke K., Chambers J.E., Diliberto J., Doerrer N.G., Driver J.H., Hastings C.E., Iyengar S., Krieger R., Stahl B., Timchalk C. The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments. Critical Reviews in Toxicology 2006, 36:9-35.
5. Bi Y.A., Kazolias D., Duignan D.B. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metabolism and Disposition 2006, 34(9):1658-1665.
6. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach S.R., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A. Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. Journal of Clinical Pharmacology 2003, 43(5):443-469.
7. Blaauboer B.J., Boobis A.R., Castell J.V., Coecke S., Groothuis G.M.M., Guillouzo A., Hall T.J., Hawksworth G.M., Lorenzon G., Miltenburger H.G., Rogiers V., Skett P., Villa P., Wiebel F.J. The practical applicability of hepatocyte cultures in routine testing. ECVAM Workshop Report No. 1. Alternatives to Laboratory Animals 1994, 22:231-241.
8. Blaauboer B.J. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicology Letters 2003, 138(1-2):161-171.
9. Bogni A., Monshouwer M., Moscone A., Hidestrand M., Ingelman-Sundberg M., Hartung T., Coecke S. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicology In Vitro 2005, 19(5):621-629.
10. Boobis A., Gundert-Remy U., Kremers P., Macheras P., Pelkonen O. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. European Journal of Pharmaceutical Sciences 2002, 17(4-5):183-193.
11. Bouvier d'Yvoire M., Prieto P., Blaauboer B.J., Bois F.Y., Boobis A., Brochot C., Coecke S., Freidig A., Gundert-Remy U., Hartung T., Jacobs M.N., Lavé T., Leahy D.E., Lennernaes H., Loizou G.D., Meek B., Pease C., Rowland M., Spendiff M., Yang J., Zeilmaker M. Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Alternatives to Laboratory Animals 2007, 35:661-671.
12. Braissant O., Henry H., Villard A.-M., Zurich M.-G., Loup M., Eilers B., Parlascino G., Matter E., Boulat O., Honegger P., Bachmann C. Ammonium-induced impairment of axonal growth is prevented through glial creatine. Journal of Neuroscience 2002, 22:9810-9820.
13. Braun H., Buhnemann C., Neumann J., Reymann K.G. Preparation of a tissue-like cortical primary culture from embryonic rats using Matrigel and serum free Start V Medium. Journal of Neuroscience Methods 2006, 15:32-38.
14. Bremer S., Pellizzer C., Coecke S., Paparella M., Catalani P. Detection of the embryotoxic potential of cyclophosphamide by using a combined system of metabolic competent cells and embryonic stem cells. Alternatives to Laboratory Animals 2002, 30:77-85.
15. Bull S., Langezaal I., Clothier R., Coecke S. A genetically engineered cell-based system for detecting metabolism-mediated toxicity. Alternatives to Laboratory Animals 2001, 29:703-716.
16. Cai H., Stoner C., Reddy A., Freiwald S., Smith D., Winters R., Stankovic C., Surendran N. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. International journal of pharmaceutics 2006, 308(1-2):133-139.
17. Chen X., Murawski A., Patel K., Crespi C.L., Balimane P.V. A novel design of artificial membrane for improving the PAMPA model. Pharmaceutical Research 2008, 25(7):1511-1520.
18. Coecke S., Rogiers V., Bayliss M., Castell J., Doehmer J., Fabre G., Fry J., Kern A., Westmoreland C. The use of long-term hepatocyte cultures for detecting induction of drug metabolizing enzymes. The current status ECVAM hepatocytes and metabolically competent systems task force Report 1. Alternatives to Laboratory Animals 1999, 27:579-638.
19. Coecke S., Bogni A., Langezaal I., Worth A., Hartung T., Monshouwer M. The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects. Toxicology In Vitro 2001, 15:553-556.
20. Coecke S., Eskes C., Gartion J., Vliet E.V., Kinsner A., Bogni A., Raimondo L., Parissis N., Langezaal I. Metabolism-mediated neurotoxicity: the significance of genetically engineered cell lines and new three-dimensional cell cultures. Alternatives to Laboratory Animals 2002, 30:115-158.
21. Coecke S., Balls M., Bowe G., Davis J., Gstraunthaler G., Hartung T., Hay R., Merten O.W., Price A., Schechtman L., Stacey G., Stokes W. Second ECVAM Task Force on Good Cell Culture Practice. Guidance on good cell culture practice. A report of the second ECVAM task force on good cell culture practice. Alternatives to Laboratory Animals 2005, 33(3):261-287.
22. Coecke S., Blaauboer B.J., Elaut G., Freeman S., Freidig A., Gensmantel N., Hoet P., Kapoulas V.M., Ladstetter B., Langley G., Leahy D., Mannens G., Meneguz A., Monshouwer M., Nemery B., Pelkonen O., Pfaller W., Prieto P., Proctor N., Rogiers V., Rostami-Hodjegan A., Sabbioni E., Steiling W., van de Sandt J.J. Toxicokinetics and metabolism. Alternatives to Laboratory Animals 2005, 33(1):147-175.
23. Coecke S., Ahr H., Blaauboer B.J., Bremer S., Casati S., Castell J., Combes R., Corvi R., Crespi C.L., Cunningham M.L., Elaut G., Eletti B., Freidig A., Gennari A., Ghersi-Egea J.F., Guillouzo A., Hartung T., Hoet P., Ingelman-Sundberg M., Munn S., Janssens W., Ladstetter B., Leahy D., Long A., Meneguz A., Monshouwer M., Morath S., Nagelkerke F., Pelkonen O., Ponti J., Prieto P., Richert L., Sabbioni E., Schaack B., Steiling W., Testai E., Vericat J.A., Worth A. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM Workshop 54. Alternatives to Laboratory Animals 2006, 34(1):49-84.
24. Coecke S., Goldberg A.M., Allen S., Buzanska L., Calamandrei G., Crofton K., Hareng L., Hartung T., Knaut H., Honegger P., Jacobs M., Lein P., Li A., Mundy W., Owen D., Schneider S., Silbergeld E., Reum T., Trnovec T., Monnet-Tschudi F., Bal-Price A. Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Environmental Health Perspectives 2007, 115(6):924-931.
25. Clemedson C., Blaauboer B., Castell J., Prieto P., Risteli L., Vericat J.A., Wendel A. ACuteTox - optimation and pre-validation of an in vitro test strategy for predicting human acute toxicity. Alternativen zu Tierexperimenten 2006, 23:254-258.
26. Clothier R., Gottschalg E., Casati S., Balls M. The FRAME alternatives laboratory database. 1. In vitro basal cytotoxicity determined by the Kenacid blue total protein assay. Alternatives to Laboratory Animals 2006, 34(2):151-175.
27. Combes R., Grindon C., Cronin M.T., Roberts D.W., Garrod J.F. Integrated decision-tree testing strategies for acute systemic toxicity and toxicokinetics with respect to the requirements of the EU REACH legislation. Alternatives to Laboratory Animals 2008, 36(1):91-109.
28. Cooper-Hannan R., Harbell J.W., Coecke S., Balls M., Bowe G., Cervinka M., Clothier R., Hermann F., Klahm L.K., de Lange J., Liebsch M., Vanparys P. The principles of good laboratory practice: application to in vitro toxicology studies the report and recommendations of ECVAM Workshop 37. Alternatives to Laboratory Animals 1999, 27:539-577.
29. Cui X., Thomas A., Gerlach V., White R.E., Morrison R.A., Cheng K.C. Application and interpretation of hPXR screening data: validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochemical Pharmacology 2008, 76(5):680-689.
30. Creton S., Billington R., Davies W., Dent M.P., Hawksworth G.M., Parry S., Travis K.Z. Application of toxicokinetics to improve chemical risk assessment: implications for the use of animals. Regulatory Toxicology and Pharmacology 2009, 55:291-299.
31. DeJongh J., Nordin-Andersson M., Ploeger B.A., Forsby A. Estimation of systemic toxicity of acrylamide by integration of in vitro toxicity data with kinetic simulations. Toxicology and Applied Pharmacology 1999, 158(3):261-268.
32. Delic J.I., Lilly P.D., MacDonald A.J., Loizou G.D. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride. Regulatory Toxicology and Pharmacology 2000, 32(2):144-155.
33. Dierickx P.J. Cytotoxicity of the MEIC reference chemicals in rat hepatoma-derived Fa32 cells. Toxicology 2000, 150(1-3):159-169.
34. Dierickx P.J., Scheers E.M. Neutral red uptake inhibition in adhered and adhering rat hepatoma-derived Fa32 cells to predict human toxicity. Journal of Applied Toxicology 2002, 22(1):61-65.
35. Directive 76/768/EEC of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products. Official Journal of the European Communities L262, 169-172.
36. Directive 65/65/EEC, 1965. Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products. Available from: http://www.echamp.eu/fileadmin/user_upload/Regulation/Directive_65-65-EEC__-__Consolidated_Version.pdf.
37. Dorne J.L., Renwick A.G. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicological Sciences 2005, 86(1):20-26.
38. Dorne J.L., Walton K., Slob W., Renwick A.G. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food and Chemical Toxicology 2002, 40(11):1633-1656.
39. Dorne J.L., Walton K., Renwick A.G. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food and Chemical Toxicology 2003, 41(2):225-245.
40. ECHA, 2009. ECHA/PR/09/11. New study inaccurate on the number of test animals for REACH. Available from: http://echa.europa.eu/doc/press/pr_09_11_animal_testing_20090828.pdf.
41. ECVAM Biokinetics. Alternatives to Laboratory Animals 2002, 30(1):55-70.
42. EFSA, 2007. Opinion of the Scientific Panel on Plant Protection Products and their Residues on a request from the Commission related to the revision of Annexes II and III to Council Directive 91/414/EEC concerning the placing of plant protection products on the market - toxicological and metabolism studies. 31 January 2007. Available from: http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1178620772682.htm.
43. EFSA Panel on Plant protection products and their Residues (PPR), 2007. Scientific Opinion related to the revision of Annexes II and III to Council Directive 91/414/EEC concerning the placing of plant protection products on the market: ecotoxicological studies, on request from the Commission. EFSA Journal 461, 1-44.
44. Elsby R., Surry D.D., Smith V.N., Gray A.J. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 2008, 38(7-8):1140-1164.
45. ESAC, 2001. Statement on the scientific validity of the Embryonic Stem Cell Test (EST), the Micromass Test and the Post implantation Rat Whole-Embryo Culture Assay - in vitro tests for embryo toxicity. ECVAM Scientific Advisory Committee (ESAC), 17th Meeting, 16-17 October, Ispra, Italy.
46. ESAC, 2008. Statement on the Scientific Validity of In-vitro Tests for Skin IrritationTesting. 5th November 2008. Available from: http://ecvam.jrc.it/index.htm.
47. Eskes C., Zuang V. Alternative (non-animal) methods for cosmetics testing: current status and future prospects. Alternatives to Laboratory Animals 2005, 33(1):47-81. (Chapter 9).
48. EU, 1976. Council Directive 76/768/EEC of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products. Official Journal L262, 169-200.
49. EU, 1993. Council Directive 93/35/EEC of 14 June 1993 amending for the sixth time Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products. Official Journal L151, 32-37.
50. EU, 2010. Regulation (EC) No. 1107/2009 of the European Parliament and of the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EC and 91/414/EEC.
51. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286(5439):487-491.
52. FDA, 2005. Guidance for Industry ANDAs: Impurities in Drug Substances.
53. FDA, 2006. Food and Drug Administration (FDA): Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing" 2006. Available from: http://www.fda.gov/cder/Guidance/6695dft.pdf.
54. FDA, 2008. Food and Drug Administration (FDA): Guidance for Industry Safety Testing of Drug Metabolites, February, 2008. Available from: http://www.fda.gov/CDER/GUIDANCE/6897fnl.pdf.
55. Garberg P., Ball M., Borg N., Cecchelli R., Fenart L., Hurst R.D., Lindmark T., Mabondzo A., Nilsson J.E., Raub T.J., Stanimirovic D., Terasaki T., Oberg J.O., Osterberg T. In vitro models for the blood-brain barrier. Toxicology In vitro 2005, 19(3):299-334.
56. Goebel C., Hewitt N.J., Kunze G., Wenker M., Hein D.W., Beck H., Skare J. Skin metabolism of aminophenols: human keratinocytes as a suitable in vitro model to qualitatively predict the dermal transformation of 4-amino-2-hydroxytoluene in vivo. Toxicology and Applied Pharmacology 2009, 235(1):114-123.
57. Guillouzo, A., 1998. Liver cell models in in vitro toxicology. Environmental Health Perspectives 106 (Suppl. 2), 511-532 (Review).
58. Harmsen S., Koster A.S., Beijnen J.H., Schellens J.H., Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. Drug Metabolism and Disposition 2008, 36(6):1166-1171.
59. Hartung T., Rovida C. Chemical regulators have overreached. Nature 2009, 460(7259):1080-1081.
60. Hayashi M., Kamat E., Hirose A., Takahashi M., Morita T., Ema M. In silico assessment of chemical mutagenesis in comparison with results of Salmonella microsome assay on 909 chemicals. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2005, 588(2):129-135.
61. Hewitt N.J., Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 2004, 34(3):243-256.
62. Hong M.S., Hong S.J., Barhoumi R., Burghardt R.C., Donnelly K.C., Wild J.R., Venkatraj V., Tiffany-Castiglioni E. Neurotoxicity induced in differentiated SK-N-SH-SY5Y human neuroblastoma cells by organophosphorus compounds. Toxicology and Applied Pharmacology 2003, 186:110-118.
63. Horizontal Legislation, 2008. EU Environmental Policy Handbook: Providing Tools to Achieve Environmental Objectives. Available from: http://ec.europa.eu/competition/state_aid/legislation/horizontal.html.
64. Hubatsch I., Ragnarsson E.G., Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nature Protocols 2007, 2:2111-2119.
65. ICRP, 1991. ICRP 62. Radiological protection in biomedical research, Ann. ICRP 22(3), 1991. P 062 erratum in P 075 JAICRP 27(1).
66. ICRP Publication 103. The recommendations of the international commission on radiological protection. Annals of the ICRP 2007, 1-34. Elsevier. J. Valentin (Ed.).
67. Irvine J.D., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., Grove J.R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. Journal of Pharmaceutical Sciences 1999, 88(1):28-33.
68. Janmohamed A., Dolphin C.T., Phillips I.R., Shephard E.A. Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochemical Pharmacology 2001, 62(6):777-786.
69. Jennings P., Aydin S., Bennett J., McBride R., Weiland C., Tuite N., Gruber L.N., Perco P., Gaora P.O., Ellinger-Ziegelbauer H., Ahr H.-J., Van Kooten C., Daha M.R., Prieto P., Ryan M.P., Pfaller W., McMorrow T. Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicology In Vitro 2009, 23(3):486-499.
70. Kinsner-Ovaskainen A., Akkan Z., Casati S., Coecke S., Corvi R., Dal Negro G., De Bruijn J., De Silva O., Gribaldo L., Griesinger C., Jaworska J., Kreysa J., Maxwell G., McNamee P., Price A., Prieto P., Schubert R., Tosti L., Worth A., Zuang V. Overcoming barriers to validation of non-animal partial replacement methods/Integrated Testing Strategies: the report of an EPAA-ECVAM workshop. Alternatives to Laboratory Animals 2009, 37(4):437-444.
71. Kirkland D., Aardema M., Henderson L., Mueller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutation Research 2005, 584(1-2):1-256. Erratum in: Mutation Research (2005), 588(1), 70.
72. Kneuer C., Lakoma C., Honscha W. Prediction of acute toxicity in HPCT-1E3 hepatocytoma cells with liver-like transport activities. Alternatives to Laboratory Animals 2007, 35(4):411-420.
73. Kollock R., Frank H., Seidel A., Meinl W., Glatt H. Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology 2008, 245(1-2):65-75.
74. LeBoeuf R.A., Kerckaert G.A., Aardema M.J., Gibson D.P., Brauninger R., Isfort R.J. The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals. Mutation Research 1996, 356(1):85-127.
75. Lehman A.J., Fitzhugh O.G. 100-fold margin of safety. Association of Food and Drug Officials' USQ Bulletin 1954, 18:33-35.
76. Liang M., Ramsey C.R., Knox F.G. The paracellular permeability of opossum kidney cells, a proximal tubule cell line. Kidney International 1999, 56(6):2304-2308.
77. MacGregor J.T., Collins J.M., Sugiyama Y., Tyson C.A., Dean J., Smith L., Andersen M., Curren R.D., Houston J.B., Kadlubar F.F., Kedderis G.L., Krishnan K., Li A.P., Parchment R.E., Thummel K., Tomaszewski J.E., Ulrich R., Vickers A.E., Wrighton S.A. In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicological Sciences 2001, 59(1):17-36.
78. McGee, P., 2006. The assay validation challenge. Drug Discovery & Development. Available from: http://www.dddmag.com/the-assay-validation-challenge.aspx.
79. McGinnity D.F., Riley R.J. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochemical Society Transactions 2001, 29(2):135-139.
80. Maeshima H., Ohno K., Tanaka-Azuma Y., Nakano S., Yamada T. Identification of tumor promotion marker genes for predicting tumor promoting potential of chemicals in BALB/c 3T3 cells. Toxicology In Vitro 2009, 23(1):148-157.
81. Munn G.C., Aardema M.J., Hu T., Barnett B., Kaluzhny Y., Klausner M., Karetsky V., Dahl E.L., Curren R.D. Further development of the EpiDermTM 3D reconstructed human skin micronucleus (RSMN) assay. Mutation Research 2009, 673:92-99.
82. OECD TG 428 - OECD guideline for the testing of chemicals. Skin absorption: in vitro method. 428. Adopted: 13 April 2004.
83. OECD, 2004. Advisory Document 14 of the OECD Working Group on GLP: The Application of the Principles of GLP to in vitro Studies. ECVAM & ICCVAM.
84. OECD TG 430 - OECD guideline for testing of chemicals - Draft Guideline 430: In vitro skin corrosion: transcutaneous electrical resistance test (TER), organization for economic cooperation and development. Adopted: 13 April 2004.
85. OECD TG 471 - OECD Guidelines for the Testing of Chemicals, No. 471: Bacterial Reverse Mutation Test. Adopted: 26 May 1983, up-dated: 21 July 1997.
86. OECD TG 473 - OECD Guidelines for the Testing of Chemicals, No. 473: In vitro Mammalian Chromosome Aberration Test. Adopted: 26 May 1983, up-dated: 21 July 1997.
87. OECD TG 495 - OECD Guideline for testing of chemicals, No. 495 DRAFT: In vitro Syrian Hamster Embryo (SHE) Cell Transformation Assay. Organization for Economic Cooperation and Development, Paris, draft approved.
88. Oesch F., Fabian E., Oesch-Bartlomowicz B., Werner C., Landsiedel R. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metabolism Reviews 2007, 39(4):659-698.
89. Pauwels M., Rogiers V. Safety evaluation of cosmetics in the EU. Reality and challenges for the toxicologist. Toxicology Letters 2004, 151(1):7-17.
90. Pawliszyn J. New directions in sample preparation for analysis of organic compounds. Trends in Analytical Chemistry 1995, 14(3):113-122.
91. Pelkonen O., Myllynen P., Taavitsainen P., Boobis A.R., Watts P., Lake B.G., Price R.J., Renwick A.B., Gómez-Lechón M.J., Castell J.V., Ingelman-Sundberg M., Hidestrand M., Guillouzo A., Corcos L., Goldfarb P.S., Lewis D.F. Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 2001, 31(6):321-343.
92. Pelkonen O., Turpeinen M., Uusitalo J., Rautio A., Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic & Clinical Pharmacology & Toxicology 2004, 96:167-175.
93. Plant N. Strategies for using in vitro screens in drug metabolism. Drug Discovery Today 2004, 9(7):328-336.
94. Prieto P., Blaauboer B.J., de Boer A.G., Boveri M., Cecchelli R., Clemedson C., Coecke S., Forsby A., Galla H.J., Garberg P., Greenwood J., Price A., Taehti H. Blood-brain barrier in vitro models and their application in toxicology. Alternatives to Laboratory Animals 2004, 32:37-50.
95. Renwick A.G., Lazarus N.R. Human variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regulatory Toxicology and Pharmacology 1998, 27(1 Pt. 2):3-20.
96. Rogiers V., Pauwels M. Safety Assessment of Cosmetics in Europe. Current Problems in Dermatology 2008, vol. 37. S. Karger, Basel, CH.
97. Saliner A.G., Tsakovska I., Pavan M., Patlewicz G., Worth A.P. Evaluation of SARs for the prediction of skin irritation/corrosion potential: structural inclusion rules in the BfR decision support system. SAR QSAR in Environmental Research 2007, 18(3-4):331-342.
98. SANCO, 2004. Guidance Document on Dermal Absorption (Sanco/222/2000 rev.7, 19 March 2004) European Commission, Health & Consumer Protection Directorate-General. Available from: http://ec.europa.eu/food/plant/protection/evaluation/guidance/wrkdoc20_rev_en.pdf.
99. Sanderson D.M., Earnshaw C.G. Computer prediction of possible toxic action from chemical structure; the DEREK system. Human and Experimental Toxicology 1991, 10:261-273.
100. SCCP/1005/06: The SCCP's Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation, adopted by the SCCP during the 10th plenary meeting of 19 December 2006.
101. SCCS/1358/10: SCCS (Scientific Committee on Consumer Safety). Basic criteria for the in vitro assessment of dermal absorption of cosmetic ingredients. The SCCS adopted this opinion at its 7th plenary meeting of 22 June 2010.
102. Shou M., Hayashi M., Pan Y., Xu Y., Morrissey K., Xu L., Skiles G.L. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metabolism and Disposition 2008, 36(11):2355-2370.
103. Schnackenberg, L.K., Chen, M., Sun, J., Holland, R.D., Dragan, Y., Tong, W., Welsh, W., Beger, R.D., 2008. Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicology and Applied Pharmacology [Epub ahead of print].
104. Skare J.A., Hewitt N.J., Doyle E., Powrie R., Elcombe C. Metabolite screening of aromatic amine hair dyes using in vitro hepatic models. Xenobiotica 2009, 39(11):811-825.
105. Spielmann H., Balls M., Dupuis J., Pape W.J.W., De Silva O., Holzhuetter H.G., Gerberick F., Liebsch M., Lowell W.W., Pfannenbecker V. A study on UV filter chemicals from Annex VII of the European Union Directive 76/768/EEC in the in vitro NRU Phototoxicity test. Alternatives to Laboratory Animals 1998, 26:679-708.
106. Spielmann H., Hoffmann S., Liebsch M., Botham P., Fentem J.H., Eskes C., Roguet R., Cotovio J., Cole T., Worth A., Heylings J., Jones P., Robles C., Kandárová H., Gamer A., Remmele M., Curren R., Raabe H., Cockshott A., Gerner I., Zuang V. The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. Alternatives to Laboratory Animals 2007, 35(6):559-601.
107. Thomas S., Brightman F., Gill H., Lee S., Pufong B. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. Journal of Pharmaceutical Sciences 2008, 97(10):4557-4574.
108. Tox21, 2008. Available from: http://www.epa.gov/comptox/articles/comptox_mou.html.
109. Truhaut R. The concept of the acceptable daily intake: an historical review. Food Additives and Contaminants 1991, 8:151-162.
110. Uehara T., Kiyosawa N., Shimizu T., Omura K., Hirode M., Imazawa T., Mizukawa Y., Ono A., Miyagishima T., Nagao T., Urushidani T. Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics-based approach to assessing risk of toxicity to humans. Human and Experimental Toxicology 2008, 27(1):23-35.
111. Vaes W.H.J., Urrestarazu-Ramos E., Verhaar H.J.M., Seinen W., Hermens J.L.M. Measurement of the free concentration using solid-phase microextraction: binding to protein. Analytical Chemistry 1996, 68:4463-4467.
112. Van Leeuwen C.J. General introduction. Risk Assessment of Chemicals; An Introduction 2007, 1-36. Springer, Dordrecht. second ed. C.J. Van Leeuwen, T.G. Vermeire (Eds.).
113. Vignati L., Turlizzi E., Monaci S., Grossi P., Kanter R., Monshouwer M. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 2005, 216(2-3):154-167.
114. Westerink W.M., Schoonen W.G. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicology In Vitro 2007, 21(8):1581-1591.
115. Westerink W.M., Schoonen W.G. Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicology In Vitro 2007, 21(8):1592-1602.
116. Wieser M., Stadler G., Jennings P., Streubel B., Pfaller W., Ambros P., Riedl C., Katinger H., Grillari J., Grillari-Voglauer R. HTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. American Journal of Physiology. Renal Physiology 2008, 295(5):F1365-F1375.
117. Zuber R., Anzenbacherova E., Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. Journal of Cellular and Molecular Medicine 2002, 6(2):189-198.